Immunotherapy to save the stomach or colon from surgery
Part of Cancer, Digestive system clinical trials.
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with stomach or colon cancer that hasn't spread to other organs.
- Your tumor must have a specific genetic marker called dMMR or MSI-H (a protein or gene test shows this).
- You must be healthy enough to carry out daily activities (ECOG score 0-2).
- You must be 18 years or older.
- You must not have had prior treatment with a certain type of immunotherapy (CTLA-4 blockers).
- You must not have active autoimmune diseases or serious uncontrolled health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs given before surgery for locally advanced gastric cancer that has a specific genetic marker (MSI-H or dMMR). The goal is to shrink the tumor and improve outcomes before removing it surgically.
This trial tests combining an immunotherapy drug (sintilimab) with low-dose radiation before surgery for stomach cancer that has a specific genetic marker (dMMR/MSI-H). The goal is to see if this combination can shrink the tumor and improve outcomes without needing strong chemo.
This study tests a lower dose of immunotherapy in patients with colorectal or stomach cancer that has spread or cannot be removed by surgery. The cancer must have a specific genetic feature (MSI/dMMR). The goal is to see if this approach works well with fewer side effects.
This trial tests whether giving immunotherapy before surgery can help people with a specific type of stomach cancer (dMMR/MSI-H) that can be removed. It aims to see how well the immune system responds and if the tumor shrinks.
This trial tests a chemotherapy followed by an immunotherapy drug (tislelizumab) for people with stomach or colon cancer that has certain genetic markers. It aims to prevent the cancer from coming back after surgery.
This phase 3 trial studies a PD-1 antibody medicine given after surgery to help prevent stage III colon cancer from coming back. It is specifically for people whose tumor is mismatch repair–defective (dMMR) or MSI-H, which may make the cancer more responsive to immune-based treatment.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.